- Shares of Sarepta Therapeutics (SRPT) are off 5.7% premarket.
- Likely behind the move is Citi, where SRPT is a top sell idea for 2014, along with Ariad Pharmaceuticals (ARIA).
- On SRPT, Citi doesn't "anticipate that [the] FDA will reverse its view that eteplirsen's Phase 2 data is not sufficient to file [making] the path ahead ... risky, lengthy, and expensive."
- On ARIA: "We expect the [Iclusig] re-launch to be challenging with a tightly restricted label and headwinds."
- ARIA -6.5% premarket
From other sites
Sarepta Therapeutics : Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent Corporate Developmentsat 4-traders.com (Mar 24, 2015)
at Benzinga.com (Jan 15, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 13, 2015)
at Benzinga.com (Jan 12, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs